Compare JUBILANT LIFE SCIENCES with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES STERLING BIOTECH JUBILANT LIFE SCIENCES/
STERLING BIOTECH
 
P/E (TTM) x 13.8 -0.4 - View Chart
P/BV x 2.6 0.0 18,081.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   STERLING BIOTECH
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
STERLING BIOTECH
Dec-13
JUBILANT LIFE SCIENCES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs89811 8,552.4%   
Low Rs6183 18,161.8%   
Sales per share (Unadj.) Rs572.026.8 2,133.8%  
Earnings per share (Unadj.) Rs36.2-15.0 -242.2%  
Cash flow per share (Unadj.) Rs59.5-5.5 -1,089.4%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.954.9 550.1%  
Shares outstanding (eoy) m159.28267.87 59.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 511.0%   
Avg P/E ratio x20.9-0.5 -4,501.5%  
P/CF ratio (eoy) x12.7-1.3 -1,000.8%  
Price / Book Value ratio x2.50.1 1,981.9%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6941,862 6,483.0%   
No. of employees `0002.41.4 176.5%   
Total wages/salary Rs m19,260547 3,522.2%   
Avg. sales/employee Rs Th38,120.65,303.3 718.8%   
Avg. wages/employee Rs Th8,058.4403.8 1,995.4%   
Avg. net profit/employee Rs Th2,414.3-2,959.0 -81.6%   
INCOME DATA
Net Sales Rs m91,1087,181 1,268.8%  
Other income Rs m35743 839.0%   
Total revenues Rs m91,4667,223 1,266.3%   
Gross profit Rs m17,390947 1,836.5%  
Depreciation Rs m3,7092,543 145.8%   
Interest Rs m2,1984,377 50.2%   
Profit before tax Rs m11,840-5,931 -199.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,268-1,924 -169.8%   
Profit after tax Rs m5,770-4,007 -144.0%  
Gross profit margin %19.113.2 144.7%  
Effective tax rate %27.632.4 85.1%   
Net profit margin %6.3-55.8 -11.4%  
BALANCE SHEET DATA
Current assets Rs m45,84814,335 319.8%   
Current liabilities Rs m20,89749,809 42.0%   
Net working cap to sales %27.4-494.0 -5.5%  
Current ratio x2.20.3 762.3%  
Inventory Days Days57403 14.1%  
Debtors Days Days51171 29.9%  
Net fixed assets Rs m65,49855,432 118.2%   
Share capital Rs m159268 59.5%   
"Free" reserves Rs m47,93013,935 343.9%   
Net worth Rs m48,08914,701 327.1%   
Long term debt Rs m42,4299,478 447.7%   
Total assets Rs m114,68573,988 155.0%  
Interest coverage x6.4-0.4 -1,799.3%   
Debt to equity ratio x0.90.6 136.9%  
Sales to assets ratio x0.80.1 818.6%   
Return on assets %6.90.5 1,387.1%  
Return on equity %12.0-27.3 -44.0%  
Return on capital %12.4-6.4 -193.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m12,4221,860 667.9%   
Fx outflow Rs m17,22725 69,212.5%   
Net fx Rs m-4,8051,835 -261.9%   
CASH FLOW
From Operations Rs m11,2151,719 652.5%  
From Investments Rs m-10,118-3,148 321.4%  
From Financial Activity Rs m6,5741,426 461.0%  
Net Cashflow Rs m7,612-3 -223,888.2%  

Share Holding

Indian Promoters % 45.6 33.9 134.5%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 0.0 -  
FIIs % 21.2 9.9 214.1%  
ADR/GDR % 0.0 16.9 -  
Free float % 21.1 39.3 53.7%  
Shareholders   23,815 21,482 110.9%  
Pledged promoter(s) holding % 15.9 55.9 28.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFE SCIENCES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Higher; Dow Futures Up by 204 Points(12:30 pm)

Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 378 points, up 0.7% at 49,478 levels.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Mar 1, 2021 03:12 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS